MTI-101 induces synergistic cell kill in combination with Erlotinib in EGFR-driven lung cancer models.

被引：0
|
作者：
Blumencranz, Lisa E. [1 ]
Nair, Rajesh R. [1 ]
McLaughlin, Mark L. [1 ]
Haura, Eric B. [1 ]
Hazlehurst, Lori A. [1 ]
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
来源：
CLINICAL CANCER RESEARCH | 2014年 / 20卷
关键词：
D O I：
10.1158/1078-0432.14AACRIASLC-A07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A07
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Emergence of Resistance to MTI-101 Selects for a MET Genotype and Phenotype in EGFR Driven PC-9 and PTEN Deleted H446 Lung Cancer Cell Lines
    Jones, Clark
    Dziadowicz, Sebastian
    Suite, Samuel
    Eby, Ashley
    Chen, Wei-Chih
    Hu, Gangqing
    Hazlehurst, Lori A.
    CANCERS, 2022, 14 (13)
  • [2] Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer
    Farnsworth, Dylan A.
    Chen, Yankuan T.
    de Rappard Yuswack, Georgia
    Lockwood, William W.
    CELLS, 2021, 10 (12)
  • [3] Novel compound PS-101 exhibits selective inhibition in non-small-cell lung cancer cell by blocking the EGFR-driven antiapoptotic pathway
    Zhang, Guo-Hai
    Cai, Le-Jing
    Wang, Yan-Fei
    Zhou, Yuan-Hua
    An, Yun-Feng
    Liu, Yan-Cheng
    Peng, Yan
    Chen, Zhen-Feng
    Liang, Hong
    BIOCHEMICAL PHARMACOLOGY, 2013, 86 (12) : 1721 - 1730
  • [4] EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer
    Selenz, Carolin
    Compes, Anik
    Nill, Marieke
    Borchmann, Sven
    Odenthal, Margarete
    Florin, Alexandra
    Braegelmann, Johannes
    Buettner, Reinhard
    Meder, Lydia
    Ullrich, Roland T.
    CANCERS, 2022, 14 (16)
  • [5] Circulating Proteoglycan Endocan Mediates EGFR-Driven Progression of Non-Small Cell Lung Cancer
    Yang, Yi-Chieh
    Pan, Ke-Fan
    Lee, Wei-Jiunn
    Chang, Jer-Hwa
    Tan, Peng
    Gu, Chia-Chi
    Chang, Wei-Min
    Yang, Shun-Fa
    Hsiao, Michael
    Hua, Kuo-Tai
    Chien, Ming-Hsien
    CANCER RESEARCH, 2020, 80 (16) : 3292 - 3304
  • [6] SYNERGISTIC ANTITUMOR ACTIVITY OF BEVACIZUMAB AND ERLOTINIB IN EGFR-MUTATED NON-SMALL CELL LUNG CANCER XENOGRAFT MODELS
    Moriya, Yoichiro
    Yamamoto, Kaname
    Yanagisawa, Mieko
    Yorozu, Keigo
    Kurasawa, Mitsue
    Furugaki, Koh
    Iwai, Toshiki
    Ishikura, Nobuyuki
    Harada, Naoki
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S768 - S768
  • [7] Synergistic anti-tumor effect of the combination of amrubicin and erlotinib in non-small cell lung cancer with wild type EGFR
    Otani, Sakiko
    Sasaki, Jiichiro
    Masuda, Kuniko
    Okamoto, Kazuya
    Namubu, Akiko
    Matsumoto, Toshihide
    Tanaka, Masumi
    Ishihara, Mikiko
    Nakahara, Yashiro
    Fukui, Tomoya
    Igawa, Satoshi
    Masuda, Noriyuki
    CANCER RESEARCH, 2016, 76
  • [8] Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer
    Roper, Nitin
    El Meskini, Rajaa
    Maity, Tapan
    Atkinson, Devon
    Day, Amanda
    Pate, Nathan
    Cultraro, Constance M.
    Pack, Svetlana
    Zgonc, Valerie
    Weaver Ohler, Zoe
    Guha, Udayan
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (02): : 337 - 348
  • [9] The role of autophagy and Atg3 in erlotinib-resistant lung cancer and synergistic cell death with combination of erlotinib and cisplatin
    Lee, Jasmine G.
    Wu, Reen
    CANCER RESEARCH, 2012, 72
  • [10] ANTITUMOR ACTIVITY OF BEVACIZUMAB IN COMBINATION WITH DOCETAXEL IN EGFR-TKI RESISTANT NON-SMALL CELL LUNG CANCER XENOGRAFT MODELS.
    Yamamoto, Kaname
    Yorozu, Keigo
    Kurasawa, Mitsue
    Iwai, Toshiki
    Harada, Naoki
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S768 - S769
12345